Pregabalin Capsules, we have got ANDA approval since July,2021; now the sales amount is around USD0.5 million in US market; And we have got MA in EU market; We plan to register in South East Asia market and other markets

Indication and Usage:

Management of neuropathic pain associated with diabetic peripheral neuropathy

Management of postherpetic neuralgia

Adjunctive therapy for the treatment of partial-onset seizures in patients 17 years of age and older

Management of fibromyalgia

Management of neuropathic pain associated with spinal cord injury

Pediatric use information is approved for Pfizer’s LYRICA^® (pregabalin) Capsules and Oral Solution products. However, due to Pfizer’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.